Antithyroid drug therapy of Graves’ hyperthyroidism: Realistic goals and focus on evidence

Expert Review of Endocrinology and Metabolism

Volumn 1, Issue 1, 2006, Pages 91-102

  Laurberg, Peter ^a   Andersen, Stig ^a   Karmisholt, Jesper ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

carbimazole; Graves disease; methimazole; propylthiouracil; radioiodine therapy; thyroid surgery

Indexed keywords

EID: 84992112645     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/17446651.1.1.91     Document Type: Article

References (66)

1. Bartalena L, Wiersinga WM, Pinchera A. Graves’ ophthalmopathy: state of the art and perspectives. J. Endocrinol. Invest. 27, 295–301 (2004).
2. Weetman AP. Cellular immune responses in autoimmune thyroid disease. Clin. Endocrinol. (Oxf.) 61, 405–413 (2004).
3. Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves’ disease and multinodular toxic goitre: a comparison of two competitive binding assays. Clin. Endocrinol. (Oxf.) 55, 381–390 (2001).
4. Ando T, Latif R, Davies TF. Thyrotropin receptor antibodies: new insights into their actions and clinical relevance. Best Pract. Res. Clin. Endocrinol. Metab. 19, 33–52 (2005).
5. Codaccioni JL, Orgiazzi J, Blanc P, Pugeat M, Roulier R, Carayon P. Lasting remissions in patients treated for Graves’ hyperthyroidism with propranolol alone: a pattern of spontaneous evolution of the disease. J. Clin. Endocrinol. Metab. 67, 656–662 (1988).
6. Hidaka Y, Tamaki H, Iwatani Y, Tada H, Mitsuda N, Amino N. Prediction of post-partum Graves' thyrotoxicosis by measurement of thyroid stimulating antibody in early pregnancy. Clin. Endocrinol. (Oxf.) 41, 15–20 (1994).
7. Momotani N, Noh J, Ishikawa N, Ito K. Relationship between silent thyroiditis and recurrent Graves’ disease in the postpartum period. J. Clin. Endocrinol. Metab. 79, 285–289 (1994).
8. Cooper DS. Antithyroid drugs. N. Engl. J. Med. 352, 905–917 (2005)
9. McCruden DC, Hilditch TE, Connell JM, McLellan AR, Robertson J, Alexander WD. Duration of antithyroid action of methimazole estimated with an intravenous perchlorate discharge test. Clin. Endocrinol. (Oxf.) 26, 33–39 (1987).
10. Okamura K, Ikenoue H, Shiroozu A, Sato K, Yoshinari M, Fujishima M. Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves’ hyperthyroidism. J. Clin. Endocrinol. Metab. 65, 719–723 (1987).
11. Arntzenius AB, Elte JW, Frolich M, Haak A. The significance of the initial FT4-index for the management of single daily dose methimazole treatment of hyperthyroidism. Clin. Endocrinol. (Oxf.) 29, 239–247 (1988).
12. Franklyn JA, Daykin J, Drolc Z, Farmer M, Sheppard MC. Long-term follow-up of treatment of thyrotoxicosis by three different methods. Clin. Endocrinol. (Oxf.) 34, 71–76 (1991).
13. Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin. Endocrinol. (Oxf.) 61, 641–648 (2004).
14. Barakate MS, Agarwal G, Reeve TS, Barraclough B, Robinson B, Delbridge LW. Total thyroidectomy is now the preferred option for the surgical management of Graves’ disease. ANZ J. Surg. 72, 321–324 (2002).
15. Lal G, Ituarte P, Kebebew E, Siperstein A, Duh QY, Clark OH. Should total thyroidectomy become the preferred procedure for surgical management of Graves’ disease? Thyroid 15, 569–574 (2005).
16. Benker G, Vitti P, Kahaly G et al. Response to methimazole in Graves’ disease. The European Multicenter Study Group. Clin. Endocrinol. (Oxf.) 43, 257–263 (1995).
17. Kallner G, Vitols S, Ljunggren JG. Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves’ disease. J. Intern. Med. 239, 525–529 (1996).
18. Laurberg P, Torring J, Weeke J. A comparison of the effects of propylthiouracil and methimazol on circulating thyroid hormones and various measures of peripheral thyroid hormone effects in thyrotoxic patients. Acta Endocrinol. (Copenh.) 108, 51–54 (1985).
19. Torring O, Tallstedt L, Wallin G et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine – a prospective, randomized study. The Thyroid Study Group. J. Clin. Endocrinol. Metab. 81, 2986–2993 (1996).
20. Tallstedt L, Lundell G, Torring O et al. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. The Thyroid Study Group. N. Engl. J. Med. 326, 1733–1738 (1992).
21. Bartalena L, Marcocci C, Bogazzi F et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N. Engl. J. Med. 338, 73–78 (1998).
22. Romaldini JH, Bromberg N, Werner RS et al. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves’ hyperthyroidism. J. Clin. Endocrinol. Metab. 57, 563–570 (1983).
23. Abraham P, Avenell A, Watson WA, Park CM, Bevan JS. Antithyroid drug regimen for treating Graves’ hyperthyroidism. Cochrane Database Syst. Rev. 2, CD003420 (2004).
24. Wenzel KW, Lente JR. Similar effects of thionamide drugs and perchlorate on thyroid-stimulating immunoglobulins in Graves’ disease: evidence against an immunosuppressive action of thionamide drugs. J. Clin. Endocrinol. Metab. 58, 62–69 (1984).
25. Volpe R. The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte–immunocyte signalling: a review. Curr. Pharm. Des. 7, 451–460 (2001).
26. Cho BY, Shong MH, Yi KH, Lee HK, Koh CS, Min HK. Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves’ disease. Clin. Endocrinol. (Oxf.) 36, 585–590 (1992).
27. Laurberg P. Mechanisms governing the relative proportions of thyroxine and 3, 5, 3′-triiodothyronine in thyroid secretion. Metabolism 33, 379–392 (1984).
28. Burmeister LA, Goumaz MO, Mariash CN, Oppenheimer JH. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 75, 344–350 (1992).
29. Izumi Y, Hidaka Y, Tada H et al. Simple and practical parameters for differentiation between destruction-induced thyrotoxicosis and Graves’ thyrotoxicosis. Clin. Endocrinol. (Oxf.) 57, 51–58 (2002).
30. Takamatsu J, Kuma K, Mozai T. Serum triiodothyronine to thyroxine ratio: a newly recognized predictor of the outcome of hyperthyroidism due to Graves’ disease. J. Clin. Endocrinol. Metab. 62, 980–983 (1986).
31. Prummel MF, Brokken LJ, Wiersinga WM. Ultra short-loop feedback control of thyrotropin secretion. Thyroid 14, 825–829 (2004).
32. Christensen LK, Skovsted L, Hansen JM. Protein-bound iodine during antithyroid treatment. Acta Med. Scand. 185, 483–487 (1969).
33. Wenzel KW, Lente JR. Syndrome of persisting thyroid stimulation immunoglobulins and growth promotion of goiter combined with low thyroxine and high triiodothyronine serum levels in drug treated Graves’ disease. J. Endocrinol. Invest. 6, 389–394 (1983).
34. Hegedus L, Hansen JM, Bech K et al. Thyroid stimulation immunoglobulins in Graves’ disease with goiter growth, low thyroxine and increasing triidothyronine during PTU treatment. Acta Endocrinol. (Copenh.) 107, 482–488 (1984).
35. Takamatsu J, Sugawara M, Kuma K et al. Ratio of serum triiodothyronine to thyroxine and the prognosis of triiodothyronine-predominant Graves’ disease. Ann. Intern. Med. 100, 372–375 (1984).
36. Chen JJ, Ladenson PW. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves’ disease. J. Clin. Endocrinol. Metab. 63, 102–106 (1986).
37. Weetman AP, Shepherdley CA, Mansell P, Ubhi CS, Visser TJ. Thyroid over-expression of type 1 and type 2 deiodonase may account for the syndrome of low thyroxine and increasing triiodothyronine during propylthiouracil treatment. Eur. J. Endocrinol. 149, 443–447 (2003).
38. Panzer C, Beazley R, Braverman L. Rapid preoperative preparation for severe hyperthyroid Graves’ disease. J. Clin. Endocrinol. Metab. 89, 2142–2144 (2004).
39. Ljunggren JG, Torring O, Wallin G et al. Quality of life aspects and costs in treatment of Graves’ hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Thyroid 8, 653–659 (1998).
40. Palit TK, Miller CC III, Miltenburg DM. The efficacy of thyroidectomy for Graves’ disease: a meta-analysis. J. Surg. Res. 90, 161–165 (2000).
41. Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves’ disease. J. Clin. Endocrinol. Metab. 87, 1073–1077 (2002).
42. Cooper DS. The side effects of antithyroid drugs. Endocrinologist 9, 457–476 (1999).
43. Vanek C, Samuels MH. Central nervous system vasculitis caused by propylthiouracil therapy: a case report and literature review. Thyroid 15, 80–84 (2005).
44. Slot MC, Links TP, Stegeman CA, Tervaert JW. Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: a long-term followup study. Arthritis Rheum. 53, 108–113 (2005).
45. Laurberg P, Buchholtz Hansen PE, Iverson E et al. Goitre size and outcome of medical treatment of Graves’ disease. Acta Endocrinol. (Copenh.) 111, 39–43 (1986).
46. Laurberg P, Nygaard B, Glinoer D, Grussendorf M, Orgiazzi J. Guidelines for TSH-receptor antibody measurements in pregnancy: results of an evidence-based symposium organized by the European Thyroid Association. Eur. J. Endocrinol. 139, 584–586 (1998).
47. Mandel SJ, Brent GA, Larsen PR. Review of antithyroid drug use during pregnancy and report of a case of aplasia cutis. Thyroid 4, 129–133 (1994).
48. Foulds N, Walpole I, Elmslie F, Mansour S. Carbimazole embryopathy: an emerging phenotype. Am. J. Med. Genet. A. 132, 130–135 (2005).
49. Momotani N, Yamashita R, Makino F, Noh JY, Ishikawa N, Ito K. Thyroid function in wholly breast-feeding infants whose mothers take high doses of propylthiouracil. Clin. Endocrinol. (Oxf.) 53, 177–181 (2000).
50. Azizi F, Hedayati M. Thyroid function in breast-fed infants whose mothers take high doses of methimazole. J. Endocrinol. Invest. 25, 493–496 (2002).
51. Vestergaard H, Laurberg P. Radioiodine and aggravation of Graves’ ophthalmopathy. Lancet 2 (8653), 47 (1989).
52. Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves’ ophthalmopathy. J. Clin. Endocrinol. Metab. 90, 5321–5323 (2005).
53. Polak M, Le Gac I, Vuillard E. Fetal and neonatal thyroid function in relation to maternal Graves' disease. Best Pract. Res. Clin. Endocrinol. Metab. 18, 289–302 (2004).
54. Chi SY, Hsei KC, Sheen-Chen SM, Chou FF. A prospective randomized comparison of bilateral subtotal thyroidectomy versus unilateral total and contralateral subtotal thyroidectomy for Graves’ disease. World J. Surg. 29, 160–163 (2005).
55. Dralle H, Sekulla C. Morbidity after subtotal and total thyroidectomy in patients with Graves’ disease: the basis for decision-making regarding surgical indication and extent of resection. Z. Arztl. Fortbild. Qualitatssich. 98 (Suppl. 5), 45–53 (2004).
56. Takamura Y, Nakano K, Uruno T et al. Changes in serum TSH receptor antibody (TRAb) values in patients with Graves’ disease after total or subtotal thyroidectomy. Endocr. J. 50, 595–601 (2003).
57. Shizume K. Long term antithyroid drug therapy for intractable cases of Graves’ disease. Endocrinol. Jpn 25, 377–379 (1978).
58. Slingerland DW, Burrows BA. Long-term antithyroid treatment in hyperthyroidism. JAMA 242, 2408–2410 (1979).
59. Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J. Clin. Endocrinol. Metab. 64, 1241–1245 (1987).
60. Azizi F, Ataie L, Hedayati M, Mehrabi Y, Sheikholeslami F. Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur. J. Endocrinol. 152, 695–701 (2005).
61. Nedrebo BG, Holm PI, Uhlving S et al. Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves’ disease. Eur. J. Endocrinol. 147, 583–589 (2002).
62. Glinoer D, de Nayer P, Bex M. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves’ hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur. J. Endocrinol. 144, 475–483 (2001).
63. Alexander WD, Harden RM, Koutras DA, Wayne E. Influence of iodine intake after treatment with antithyroid drugs. Lancet 2 (7418), 866–868 (1965).
64. Roti E, Gardini E, Minelli R. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves’ hyperthyroidism. J. Clin. Endocrinol. Metab. 76, 928–932 (1993).
65. Braverman LE. Iodine and the thyroid: 33 years of study. Thyroid 4, 351–356 (1994).
66. Preissner CM, Wolhuter PJ, Sistrunk JW, Homburger HA, Morris JC III. Comparison of thyrotropin-receptor antibodies measured by four commercially available methods with a bioassay that uses Fisher rat thyroid cells. Clin. Chem. 49, 1402–1404 (2003).